

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/539,735	03/30/2000	James L. Brown	DHI-03864	8888
23535	7590 06/03/2002			
MEDLEN & CARROLL, LLP			EXAMINER	
101 HOWARD STREET SUITE 350 SAN FRANCISCO, CA 94105			NOLAN, PATRICK J	
			ART UNIT	PAPER NUMBER
			1644	116
			DATE MAILED: 06/03/2002	19

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

Applicant(s)

09/539,735

Brown et al.

Examiner

Patrick J. Nolan

Art Unit **1644**



The MAILING DATE of this communication appear	rs on the cover sheet with the correspondence address			
Period for Reply	•			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be eveilable under the provisions of 37 CFR 1.136 (e). In no event, however, may e reply be timely filed after SIX (6) MONTHS from the				
mailing date of this communication.				
 If the period for reply specified ebove is less then thirty (30) days, e reply withing 16 NO period for reply is specified ebove, the meximum stetutory period will epperaillure to reply within the set or extended period for reply will, by stetute, ceus. Any reply received by the Office later then three months after the meiling date earned patent term adjustment. Sea 37 CFR 1.7D4(b). 	ly end will expire SIX (6) MDNTHS from the meiling dete of this communication.			
Status				
1) Responsive to communication(s) filed on Mar 8,	2002 .			
2a) X This action is FINAL. 2b) This a	ction is non-final.			
3) Since this application is in condition for allowance closed in accordance with the practice under Exp.	e except for formal matters, prosecution as to the merits is parte Quayle, 1935 C.D. 11; 453 O.G. 213.			
Disposition of Claims				
4) 💢 Claim(s) <u>1, 3-16, and 18</u>	is/are pending in the application.			
	is/are withdrawn from consideration.			
5) Claim(s)	is/are allowed.			
6) X Claim(s) 1, 3-16, and 18				
	is/are objected to.			
_	are subject to restriction and/or election requirement.			
Application Papers				
9) \square The specification is objected to by the Examiner.				
10) The drawing(s) filed on is/a	re a) \square accepted or b) \square objected to by the Examiner.			
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).				
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examine				
If approved, corrected drawings are required in reply to this Office action.				
12) The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. §§ 119 and 120				
13) ☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).				
a) \square All b) \square Some* c) \square None of:				
1. Certified copies of the priority documents have been received.				
2. \square Certified copies of the priority documents ha	ve been received in Application No			
application from the international Bur	documents have been received in this National Stage eau (PCT Rule 17.2(a)).			
*See the attached detailed Office action for a list of t				
14) Acknowledgement is made of a claim for domesti				
a) L The translation of the foreign language provision				
15) Acknowledgement is made of a claim for domesti	c priority under 35 U.S.C. §§ 120 and/or 121.			
Attachment(s) 1) Notice of References Cited (PTO-892)	41 The state of th			
Notice of neterences Creat (PTO-892) Notice of Draftsperson's Petent Drewing Review (PTO-948)	4) Interview Summery (PTO-413) Peper No(s).			
3) Information Disclosure Stetement(s) (PTO-1449) Peper No(s) 6) Other:				
The state of the s	·,			

Serial Number: 09/539,735

Art Unit: 1644

Claims 1, 3-16 and 18 are pending.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. § 103 which forms the basis for all obviousness rejections set forth in this Office action:

A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Subject matter developed by another person, which qualifies as prior art only under subsection (f) or (g) of section 102 of this title, shall not preclude patentability under this section where the subject matter and the claimed invention were, at the time the invention was made, owned by the same person or subject to an obligation of assignment to the same person.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

2. Claims 1, 3-16 and 18 stand rejected under 35 U.S.C. § 103 as being unpatentable over Evans et al. (17 on the IDS), in view of Yamashiro et al. (49 on the IDS), all of record for reasons set forth in Paper No. 10.

Applicant's arguments set forth in Paper No. 11 have been fully considered but are not found persuasive.

Applicant argues that Yamashiro et al., teaches away from the claimed invention because Yamashiro et al., demonstrates that the effect of PEG on a particular biological response in porcine thyroid cells does not correlate with a similar biological response in Evans et al.'s CHO-RLUC cells. The Examiner after reviewing the Yamashiro et al., reference found no such teaching.

Applicant argues that Yamashiro et al., teaches their PEG induced effect was limited to TSAB and did not extend to bTSH, while Applicant's specification clearly teaches said PEG inducing effect extended to bTSH.

The bTSH limitations are not claimed.

Applicant argues there was no expectation of success in

Serial Number: 09/539,735

Art Unit: 1644

creating Applicant's claimed invention, since going from Yamashiro's PTC cells to Evan's CHO-Rluc cells would not be expected to work.

However, Attorney's argument does replace evidence is required, see MPEP 2145.

Furthermore, Yamashiro's PTC cells and Evan's CHO-Rluc cells are similar in that they both express the TSH receptor, the PTC cells do it naturally while the CHO-Rluc cells do it recombinantly. Furthermore Yamashiro teaches the PEG induced effect was specific to TSAB, thereby demonstrating that PEG induced an effect specific between TSAB and the TSH receptor. Since Evans et al.'s, assay teaches both the TSAB and the TSH receptor, there is a reasonable expectation of success that using PEG would induce similar effects as those taught by Yamashiro et al.

3. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

- 4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Monday through Friday from 8:30 am to 4:30 pm.
- 5. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7939. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Patrick J. Nolan, Ph.D.

Primary Examiner, Group 1640

June 3, 2002

Tata Molan